Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Policosanol: a new treatment for cardiovascular disease?

Janikula M.

Altern Med Rev. 2002 Jun;7(3):203-17. Review.

2.

Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.

Gouni-Berthold I, Berthold HK.

Am Heart J. 2002 Feb;143(2):356-65. Review.

PMID:
11835043
3.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
4.

Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol.

Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G.

Pharmacotherapy. 2005 Feb;25(2):171-83. Review.

PMID:
15767233
5.

Policosanols as nutraceuticals: fact or fiction.

Marinangeli CP, Jones PJ, Kassis AN, Eskin MN.

Crit Rev Food Sci Nutr. 2010 Mar;50(3):259-67. doi: 10.1080/10408391003626249. Review.

PMID:
20301014
6.

Role of policosanols in the prevention and treatment of cardiovascular disease.

Varady KA, Wang Y, Jones PJ.

Nutr Rev. 2003 Nov;61(11):376-83. Review.

PMID:
14677572
7.

Management of hypercholesterolaemia in the patient with diabetes.

Packard C, Olsson AG.

Int J Clin Pract Suppl. 2002 Jul;(130):27-32. Review.

PMID:
12296606
8.

Policosanol.

Pepping J.

Am J Health Syst Pharm. 2003 Jun 1;60(11):1112-5. Review. No abstract available.

PMID:
12816020
9.
10.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
11.
12.
13.

[Diabetes and lipids].

Lechleitner M, Drexel H.

Wien Med Wochenschr. 2003;153(21-22):469-73. Review. German.

PMID:
14679889
14.

Lipid-modifying drugs.

Simons LA, Sullivan DR.

Med J Aust. 2005 Mar 21;182(6):286-9. Review.

PMID:
15777144
15.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program..

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
16.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program..

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

17.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute.; American College of Cardiology Foundation.; American Heart Association..

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

18.

[Stanols--a new perspective in treatment of hypercholesterolemia?].

Jankowski P, Bilo G, Bryniarski L, Bryniarska-Mirek E, Pajak A.

Przegl Lek. 2000;57(11):655-8. Review. Polish.

PMID:
11293214
19.

[New possibilities of correction of hypercholesterolemia in patients with diabetes mellitus].

Pan'kiv VI.

Lik Sprava. 2014 May-Jun;(5-6):56-67. Review. Russian.

PMID:
25906648
20.

Fish oil: what is the role in cardiovascular health?

Brinson BE, Miller S.

J Pharm Pract. 2012 Feb;25(1):69-74. doi: 10.1177/0897190011406983. Review.

PMID:
21676848

Supplemental Content

Support Center